CA1048931A - Bacterial antigen composition for treatment of oto-rhinolaringological infections - Google Patents
Bacterial antigen composition for treatment of oto-rhinolaringological infectionsInfo
- Publication number
- CA1048931A CA1048931A CA75234882A CA234882A CA1048931A CA 1048931 A CA1048931 A CA 1048931A CA 75234882 A CA75234882 A CA 75234882A CA 234882 A CA234882 A CA 234882A CA 1048931 A CA1048931 A CA 1048931A
- Authority
- CA
- Canada
- Prior art keywords
- staphylococcus aureus
- antigenic
- weight
- streptococcus
- fractions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000001580 bacterial effect Effects 0.000 title claims description 9
- 238000011282 treatment Methods 0.000 title abstract description 15
- 208000015181 infectious disease Diseases 0.000 title abstract description 7
- 239000000427 antigen Substances 0.000 title description 10
- 108091007433 antigens Proteins 0.000 title description 10
- 102000036639 antigens Human genes 0.000 title description 10
- 230000000890 antigenic effect Effects 0.000 claims abstract description 88
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 32
- 241000194017 Streptococcus Species 0.000 claims abstract description 23
- 241000193998 Streptococcus pneumoniae Species 0.000 claims abstract description 22
- 241000588653 Neisseria Species 0.000 claims abstract description 19
- 241000193996 Streptococcus pyogenes Species 0.000 claims abstract description 19
- 230000009089 cytolysis Effects 0.000 claims abstract description 14
- 108090000526 Papain Proteins 0.000 claims abstract description 11
- 239000004365 Protease Substances 0.000 claims abstract description 11
- 102000004142 Trypsin Human genes 0.000 claims abstract description 11
- 108090000631 Trypsin Proteins 0.000 claims abstract description 11
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 11
- 229940055729 papain Drugs 0.000 claims abstract description 11
- 235000019834 papain Nutrition 0.000 claims abstract description 11
- 239000012588 trypsin Substances 0.000 claims abstract description 11
- 235000015097 nutrients Nutrition 0.000 claims abstract description 9
- 238000009826 distribution Methods 0.000 claims abstract description 6
- 239000002609 medium Substances 0.000 claims description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical class N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 claims description 3
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229910052500 inorganic mineral Chemical class 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 239000011707 mineral Chemical class 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 235000019837 monoammonium phosphate Nutrition 0.000 claims description 3
- 239000006012 monoammonium phosphate Substances 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 3
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims 4
- 230000000415 inactivating effect Effects 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 101000795130 Homo sapiens Trehalase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042343 Subcutaneous abscess Diseases 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940076156 streptococcus pyogenes Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
ANTI-GENIC COMPOSITION
ABSTRACT
The present, invention relates to a new product for the treatment of infections in the oto-rhino-laryngo-logical field constituted by purified antigenic fractions of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus 147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209 and Diplococcus Pneumoniae 210 and Neisseria catarrhalis 987, of the catalogue of the collection of the Centre International de Distribution de Souches and d'Informations sur les Types Microbiens of Lausanne.
The antigenic fractions of the nine strains are obtained by culture in a nutrient medium, enzymatic lysis with papain and then trypsin, purification and lyophilisation.
ABSTRACT
The present, invention relates to a new product for the treatment of infections in the oto-rhino-laryngo-logical field constituted by purified antigenic fractions of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus 147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209 and Diplococcus Pneumoniae 210 and Neisseria catarrhalis 987, of the catalogue of the collection of the Centre International de Distribution de Souches and d'Informations sur les Types Microbiens of Lausanne.
The antigenic fractions of the nine strains are obtained by culture in a nutrient medium, enzymatic lysis with papain and then trypsin, purification and lyophilisation.
Description
lOg8931 The present invention relates to a new industrial product constituted by a therapeutic composition for nasal use containing antigens of bacterial origin. It also relates to the process for preparing the said composition, as well as to the application of the said composition for the treatment of infectious manifestations in the oto-rhino-laryngological field and in particular rhinitis and rhino-pharyngitis, otitis and sinusitis.
The new nasal composition according to the invention is characterised in that it contains 3 parts by weight of purified antigenic fraction of Staphylococcus aureus 634, 3 parts by weight of purified antigenic fraction of Staphylococcus aureus 636, 3 parts by weight of purified antigenic fraction of Staphylococcus aureus 659, 3 parts by weight of purified antigenic fraction of Streptococcus 147, 3 parts by weight of purified antigenic fraction of Streptococcus pyogenes 155, 3 parts by weight of purified antigenic fraction of Streptococcus_pyogenes 1178, 3 parts by weight of purified antigenic fraction of Diplococcus pneumoniae 209, 3 parts by weight of purified antigenic fraction of Diplococcus pneumoniae 210 and 1 part by weight of purified antigenic fraction of Neisseria catarrhalis 987, and is prepared by the process described below or by an obvious chemical equivalent thereof.
The numbers of the strains which are given above are those of the catalogue of the collection of the Centre International de Distribution de Souches et d'Informations sur les Types Microbiens of Lausanne.
The nine strains from which are derived the puri-fied antigenic fractions which enter into the compositionaccording to the invention and which form part of the ~' iC)48931 pathogenic strains frequently encountered clinically and towards which it is of particular interest to produce immunity have been selected for their ability to produce antigens.
Of course, without departing from the scope of the invention, the purified antigenic fractions extracted from these nine strains may be associated with other ingredients, as will be seen hereinafter in Example B.
In accordance with the present invention, there is provided a process for the preparation of a therapeutically-active product, which comprises separately cultivating in a liquid nutrient medium containing a source of carbon, a source of nitrogen and mineral salts the strains of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209, Diplococcus pneumoniae 210 and Neisseria catarrhalis 987 of the catalogue of the collection of the Centre International de Distribution de Souches et d'Informa-tions sur les Types Microbiens of Lausanne; for each of the strains, effecting enzymatic lysis of the strain in the culture medium at 60 to 65C using papain and then at 37C
using trypsin, destroying each enzyme after use by heating at lO0~ to 120C for 30 minutes, eliminating solid substances of bacterial origin which result from the lysi by centrifuging, adsorbing the antigenic fraction contained in the liquid medium after centrifuging on a solid support, separating the solid support from the liquid phase by centrifuging, eluting the antigenic fraction from the support using an aqueous solution of ammonia, evaporating ammonia from the eluate, concentrating the eluate, and lyophilising the concentrate ~ _ 3 ~, eluate to obtain the antigenic fraction in the form of powder; and mixing the separately-obtained lyophilised antigenic Eractions in the proportions of 3 parts by weight of each of the lyophilised antigenic fraction~ of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus 147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209 and Diplococcus pneumoniae 210 and 1 part by weight of the lyophilised antigenic fraction of Neisseria catarrhalis 987.
The extraction of the purified antigenic fractions generally necessitates two different culture media, each containing a source of carbon, a source of nitrogen and mineral salts:
A11, 1048~31 a) one med~um for the Stap~Llococcus aureus, the Streptococcus and the Diplococcus pneumoniae strains;
this medium is prepared in a vessel with a volume of 300 litres, and b) a special medium for the Neisseria catarrhalis;
this medium is prepared in a 5-litre flask.
Although it is possible to cultivate the eight strains of Staphylococcus, Streptococcus and DiPlococcus simultaneously 2nd extract their antigenic fractions sim-ultaneously, it is preferred to operate strain by strain so as to avoid any possible additional risk of contamination and especially so as proportion each of the antigenic fractions better at the time of the final mixing.
Other advantages and characteristics of the invention will be better understood on reading the following non-limitative Examples.
Example A
I - PreParation of each of the purified anti~enic fractions of Staphylococcus aureus, Streptococcus and Diplococcus pne _ niae 1) Culture medium NaCl 1,500 g Dipotassium phosphate 1,500 g Monopotassium phosphate 600 g Monoammonium phosphate 600 g Glucose 1,500 g Magnesium sulphate 60 g Glycerin 600 g Yeast autolyzate 600 g Manganese sulphate 6 g Thiamine hydrochloride 1-,50 g Pyridoxine hydrochloride 1-50 g 1~)4893~
Calcium pantothenate 1-50 g Nicotinic acid 1-50 g Riboflavin 075 g Water Quantity sufficient for 300 litres The constituents of the culture medium are dissolved in 50 litres of water while stirring. After making up the volume to 300 litres with water, the pH is adjusted to 7-8 by adding soda. After fresh stirring, the medium is sterilized at 100-120C, preferably at 110C for 30 minutes.
The new nasal composition according to the invention is characterised in that it contains 3 parts by weight of purified antigenic fraction of Staphylococcus aureus 634, 3 parts by weight of purified antigenic fraction of Staphylococcus aureus 636, 3 parts by weight of purified antigenic fraction of Staphylococcus aureus 659, 3 parts by weight of purified antigenic fraction of Streptococcus 147, 3 parts by weight of purified antigenic fraction of Streptococcus pyogenes 155, 3 parts by weight of purified antigenic fraction of Streptococcus_pyogenes 1178, 3 parts by weight of purified antigenic fraction of Diplococcus pneumoniae 209, 3 parts by weight of purified antigenic fraction of Diplococcus pneumoniae 210 and 1 part by weight of purified antigenic fraction of Neisseria catarrhalis 987, and is prepared by the process described below or by an obvious chemical equivalent thereof.
The numbers of the strains which are given above are those of the catalogue of the collection of the Centre International de Distribution de Souches et d'Informations sur les Types Microbiens of Lausanne.
The nine strains from which are derived the puri-fied antigenic fractions which enter into the compositionaccording to the invention and which form part of the ~' iC)48931 pathogenic strains frequently encountered clinically and towards which it is of particular interest to produce immunity have been selected for their ability to produce antigens.
Of course, without departing from the scope of the invention, the purified antigenic fractions extracted from these nine strains may be associated with other ingredients, as will be seen hereinafter in Example B.
In accordance with the present invention, there is provided a process for the preparation of a therapeutically-active product, which comprises separately cultivating in a liquid nutrient medium containing a source of carbon, a source of nitrogen and mineral salts the strains of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209, Diplococcus pneumoniae 210 and Neisseria catarrhalis 987 of the catalogue of the collection of the Centre International de Distribution de Souches et d'Informa-tions sur les Types Microbiens of Lausanne; for each of the strains, effecting enzymatic lysis of the strain in the culture medium at 60 to 65C using papain and then at 37C
using trypsin, destroying each enzyme after use by heating at lO0~ to 120C for 30 minutes, eliminating solid substances of bacterial origin which result from the lysi by centrifuging, adsorbing the antigenic fraction contained in the liquid medium after centrifuging on a solid support, separating the solid support from the liquid phase by centrifuging, eluting the antigenic fraction from the support using an aqueous solution of ammonia, evaporating ammonia from the eluate, concentrating the eluate, and lyophilising the concentrate ~ _ 3 ~, eluate to obtain the antigenic fraction in the form of powder; and mixing the separately-obtained lyophilised antigenic Eractions in the proportions of 3 parts by weight of each of the lyophilised antigenic fraction~ of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus 147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209 and Diplococcus pneumoniae 210 and 1 part by weight of the lyophilised antigenic fraction of Neisseria catarrhalis 987.
The extraction of the purified antigenic fractions generally necessitates two different culture media, each containing a source of carbon, a source of nitrogen and mineral salts:
A11, 1048~31 a) one med~um for the Stap~Llococcus aureus, the Streptococcus and the Diplococcus pneumoniae strains;
this medium is prepared in a vessel with a volume of 300 litres, and b) a special medium for the Neisseria catarrhalis;
this medium is prepared in a 5-litre flask.
Although it is possible to cultivate the eight strains of Staphylococcus, Streptococcus and DiPlococcus simultaneously 2nd extract their antigenic fractions sim-ultaneously, it is preferred to operate strain by strain so as to avoid any possible additional risk of contamination and especially so as proportion each of the antigenic fractions better at the time of the final mixing.
Other advantages and characteristics of the invention will be better understood on reading the following non-limitative Examples.
Example A
I - PreParation of each of the purified anti~enic fractions of Staphylococcus aureus, Streptococcus and Diplococcus pne _ niae 1) Culture medium NaCl 1,500 g Dipotassium phosphate 1,500 g Monopotassium phosphate 600 g Monoammonium phosphate 600 g Glucose 1,500 g Magnesium sulphate 60 g Glycerin 600 g Yeast autolyzate 600 g Manganese sulphate 6 g Thiamine hydrochloride 1-,50 g Pyridoxine hydrochloride 1-50 g 1~)4893~
Calcium pantothenate 1-50 g Nicotinic acid 1-50 g Riboflavin 075 g Water Quantity sufficient for 300 litres The constituents of the culture medium are dissolved in 50 litres of water while stirring. After making up the volume to 300 litres with water, the pH is adjusted to 7-8 by adding soda. After fresh stirring, the medium is sterilized at 100-120C, preferably at 110C for 30 minutes.
2) Supp~:~ of tbe str~
m e strains intended for extracting the antigenic fractions are supported by passing them on to Swiss Albino mice so as to preserve their pathogenic character and their biochemical properties. Inoculation of the animal is effected intravenously.
Immediately on the death of the animals by septicaemia, blood is removed sterilely by cardiac puncture, and a liquid enrichment medium is inoculated therewith and then, from the liquid medium, a solid isolation medium.
With the pure culture obtained in this way there is inoculated a suitable quantity of liquid medium, intended to serve as inoc~lum ~or the commercial culture, in accordance with the method described in 3 hereunder .
After each new isolation, the conformity of the biochemical characteristics is checked by con~entional identification techm ques.
m e strains intended for extracting the antigenic fractions are supported by passing them on to Swiss Albino mice so as to preserve their pathogenic character and their biochemical properties. Inoculation of the animal is effected intravenously.
Immediately on the death of the animals by septicaemia, blood is removed sterilely by cardiac puncture, and a liquid enrichment medium is inoculated therewith and then, from the liquid medium, a solid isolation medium.
With the pure culture obtained in this way there is inoculated a suitable quantity of liquid medium, intended to serve as inoc~lum ~or the commercial culture, in accordance with the method described in 3 hereunder .
After each new isolation, the conformity of the biochemical characteristics is checked by con~entional identification techm ques.
3) Pre~aration of the commercial inoculum The inoculation with the pure culture obtained previously is effected on 10 ml of liquid medium (described in 1). After remaining for 24 hours in an incubator at 37C, this volume is introduced sterilely into 5 litres of medium of the same composition, previously sterilized. After 11~48931 remaining for 24 hours in an incubator at 37C, this volume is introduced sterilely into 300 litres of the same medium which has been previously sterilized.
4) Culture The temperature o~ the medium being maintained at 37C, the culture is carried out over 24 hours, aeration of the medium being ensured by the admission of filtered air (obtained by means of a Millipore diaphragm for e~ample). After 24 hours, the culture is stopped by sterilization of the medium for 1 hour at 100-120C.
At this stage, 10 ml of medium are removed under aseptic conditions for a sterility check~
At this stage, 10 ml of medium are removed under aseptic conditions for a sterility check~
5) Lysis of the bacteria This operation is effected by enzymatic hydrolysis and has the aim of liberating the antigenic fractions in the medium. After checking the sterility of the medi~um, enzymatic hydrolsis is performed in two stages:
firstly, at 60-65C by means o~ papain at pH 6-5, then, at 37C by means of trypsin at pH 7.
The object of the enzymatic lysis is to degrade the above bacterial cell so that the culture medium of point 4) above (in which the enzymatic lysis is effected and which is brought to pH 6-5 for the treatment with papain and then to pH 7 for the treatment with trypsin) is enriched with anti-gens.
The amounts of papain and trypsin are not critical.
In fact, the simplified mechanism is as follows.
The enzymes (even when present in small amount) destroy the cell wall and lay bare a portion of the cytoplasmic membrane;
the said membrane is then destroyed by reason of (i) the 1~48931 - -difference is osmotic pressure existing between the cyto-plasmic mass and the enzymatic lysis medium, and/or (ii) the enzymatic degradation; the result ~s that the antigens (located in the cell wall and located especially inside the cytoplasmic membrane), or at least a part thereo~, pass into the enzymatic lysis medium. Generally speaking, it can be considered that the enzymes enable the antigens to be separated from the substances covering or enveloping .them or from any possible substrates to which they are bound, and a bacterial extract (antigenic fraction) to be recovered which is obtained from each complete antigen and has preserved in its structure the antigenic sites of the complete antigen.
Moreover, the durations of treatment, which depend on the amounts of enzyme, are not critical either.
To obtain good results as regards the amount and the quality of the antigens extracted, it is recommended that: .
- 25 to 35 g of papain tContainirlg 660 units per milligram of enzyme, see the French Pharmacopoeia of 1949 for the definition of this content) be employed for 300 litres of medium, the treatment being effected at pH 6-5 and at 60-65C for 3 hours;
- heating be carried out at 100-120C for 30 minutes to destroy the papain;
- 12 to 18 g of trypsin (containing at least 30 International Units per milligram of enzyme, see the French Pharmacopoeia of 1965 for the definition of this content) be then employed for 300 l~tres of ~. medium, the treatment being effected at pH 7 and at 1~48931 37C for 3 hours~ and - heating be carried Ollt at 100-120C for 30 minutes to destroy the trypsin.
In the present Exarnple, the following conditions were applied, namely: treatment with 30 g of papain (con-taining 660 U/mg) for 300 litres of medium at pH 6.5 and at 60C for 3 hours; heating at 100C for 30 minutes; treat-ment with 15 g of trypsin (containing at least 30 I.U./mg for 300 litres of medium at pH 7 and at 37C for 3 hours, and then heating at 100C for 30 minutes.
firstly, at 60-65C by means o~ papain at pH 6-5, then, at 37C by means of trypsin at pH 7.
The object of the enzymatic lysis is to degrade the above bacterial cell so that the culture medium of point 4) above (in which the enzymatic lysis is effected and which is brought to pH 6-5 for the treatment with papain and then to pH 7 for the treatment with trypsin) is enriched with anti-gens.
The amounts of papain and trypsin are not critical.
In fact, the simplified mechanism is as follows.
The enzymes (even when present in small amount) destroy the cell wall and lay bare a portion of the cytoplasmic membrane;
the said membrane is then destroyed by reason of (i) the 1~48931 - -difference is osmotic pressure existing between the cyto-plasmic mass and the enzymatic lysis medium, and/or (ii) the enzymatic degradation; the result ~s that the antigens (located in the cell wall and located especially inside the cytoplasmic membrane), or at least a part thereo~, pass into the enzymatic lysis medium. Generally speaking, it can be considered that the enzymes enable the antigens to be separated from the substances covering or enveloping .them or from any possible substrates to which they are bound, and a bacterial extract (antigenic fraction) to be recovered which is obtained from each complete antigen and has preserved in its structure the antigenic sites of the complete antigen.
Moreover, the durations of treatment, which depend on the amounts of enzyme, are not critical either.
To obtain good results as regards the amount and the quality of the antigens extracted, it is recommended that: .
- 25 to 35 g of papain tContainirlg 660 units per milligram of enzyme, see the French Pharmacopoeia of 1949 for the definition of this content) be employed for 300 litres of medium, the treatment being effected at pH 6-5 and at 60-65C for 3 hours;
- heating be carried out at 100-120C for 30 minutes to destroy the papain;
- 12 to 18 g of trypsin (containing at least 30 International Units per milligram of enzyme, see the French Pharmacopoeia of 1965 for the definition of this content) be then employed for 300 l~tres of ~. medium, the treatment being effected at pH 7 and at 1~48931 37C for 3 hours~ and - heating be carried Ollt at 100-120C for 30 minutes to destroy the trypsin.
In the present Exarnple, the following conditions were applied, namely: treatment with 30 g of papain (con-taining 660 U/mg) for 300 litres of medium at pH 6.5 and at 60C for 3 hours; heating at 100C for 30 minutes; treat-ment with 15 g of trypsin (containing at least 30 I.U./mg for 300 litres of medium at pH 7 and at 37C for 3 hours, and then heating at 100C for 30 minutes.
6) Extraction of the anti~enic fractions -First of all, the elimination of the bacterial substances is carried out by centrifuging. The 300 litres of culture medium containing the antigenic fractions are then recovered. These antigenic fractions are then adsorbed on activated carbon ("OENO" (Trademark) carbon, for example).
A fresh passage through a centrifuge is carried out in order to recover the antigenic fractions adsorbed on the carbon, which will then be eluted with the aid of an aqueous solution of ammonia.
The antigenic fractions are then contained in the ammonia water.
The solution undergoes treatment in an evaporator, the object of this operation being to eliminate the ammonia and concentrate the aqueous solution. The concentration of the said aqueous solution is effected under conventional conditions; the aim to be attained is an antigenic fraction content which can be lyophilised. It is thus possible to concentrate from 2 volumes to 1 volume or, better still, from 5 volumes or more to 1 volume.
~,~,' ~48931 The lyophilisation of this aqueous solution constitutes the final stage of the extraction.
The purified antigenic fractions are then in the form of powder.
II - PreParation of the anti~enic fraction extracted from Neisseria Catarrhalis In this instance there is no change of principle, but the culture medium is different (this is due to the difficulty of cultivating this germ); moreover, the culture is performed in a 5-litre flask and lasts for 48 hours.
Only the differences in comparison with the preparation of the antigenic ~ractions extracted from Staphylococcus aureus, Streptococcus and Diplococcus Pneumoniae are given here.
Culture medium Horse serum 250 ml T broth quantitr æufficient for5 litres Composition of the T broth Peptone 200 g Glucose 10 g NcCl 25 g Distilled water quantity sufficient for 5 litres For the preparation of this medium, the horse serum is introduced sterilely into the sterile T broth and the pH is adjusted to 7-2.
The medium is then sterilized at 100C for 45 minutes.
The lysis of the bacteria, the extraction of the antigenic fractions and then the lyophilisation are then effected by the method hereinbefore described for the -1~)4893~
Staph~lococcus, Streptocooous and Diplococcus.
The molecular weight of each of the 9 antigenic fractions obtained according to ~ and II is about 12,000.
III - Mixin~ of the various anti~enio ~ractions 1 part by weight of the purified and lyophilised antigenic fraction of Neisseria catarrhalis is mixed with 3 parts by weight of each of the purified and lyophilised antigenic fractions of ~ aureus 634, 636 and 659, Streptococcus 147, 155 and 1178 and Diplococcus Pneumoniae 209 and 210.
Example B
The preferred composition according to the invention was prepared by reproducing Example A and mixing the antigenic fractions of the nine straîns in Stage III with sodium mercuro-thiolate, sodium chloride and water so as to obtain the following formulation:
Composition I:
Purified antigenic fraction extracted from ~ 634 3 mg Purified antigenic fraction extracted from Staphylococcus aureus 636 3 mg Purified antigenic fraction extracted from 5taphylococcus aureus 659 3 mg Purified antigenic fraction extracted from Streptococcus 147 3 mg Purified antigenic fraction extracted from Streptococcus p,~og~nes 155 3 mg Purified antigenic fraction extracted from Streptococcus E~ 1178 3 mg Purified antigenic fraction extracted from Diplococcus pneumonia 209 3 mg Purifled antigenic fraction extracted from DiPloc_ccus ~a~ 210 3 mg Purified antigenic fraction extracted from Neisseria catarrhalis 1 mg Sodium mercurothiolate 0-25 mg Sodium chloride 90 mg Distilled water quantity sufficient for 10 ml ~ y proceeding as above, a composition II was prepared observing the proportion of composition I.
Composition II
Purified antigenic fraction extracted from Staph,ylococcus aureus 634 4-5 mg Purified antigenic fraction extracted from StaphYlococcus aureus 636 4-5 mg Purified antigenic fraction extracted from Staph~lococcus aureus 659 4 ~ 5 mg Purified antigenic fraction extracted from Streptococcus 147 4a5 mg Purified antigenic fraction extracted from Streptococcus P~o~e-n-es 155 4 - 5 mg Purified antigenic fraction extracted from Strept coccus pyo~enes 1178 4~5 mg Purified antigenic fraction extracted from Diplococcus pneumoniae 209 4~ 5 mg Purified antigenic fraction extracted from Diploc_ccus pn,eumon,iae 210 4 ~ 5 mg Purified antigenic fraction extracted from Neisseria catarrhalis 987 1 5 mg ~ ; ~
Sodium mercurothiolate o~ 375 mg Sodium chloride 135 mg Distilled water quantity sufficient for 15 ml 16~48931 Composition II packaged in 15 ml bottles for the purpose of being administered by spraying into the nasal fossae has been called provisionally by the names "Rhinapten"
and "Rhinapten Nebuliseur". The results of the pharmacological ~5 and clinical tests which have been undertaken are summarized hereinafter.
Toxicity Study of the acute toxicity in mice, per os, has enabled it to be shown that the LD~0 (minimum mortal dose) of each of the nine antigenic fractions entering into compositions I and II is higher than 4 g/kg. It has also been shown that the LD-0 of the mixture of the nine anti-genic fractions is distinctly higher than 108 g/kg and that the LD-0 o~ compositions I and II is e~ual to 40 ml/kg (which corresponds to a dose of the mixture of the nine antigenic fractions of 100 mg/kg).
Study of the actue toxicity in mice and rats, ~er os, of the mixture of the nine antigenic fractions entering into compositions I and II at doses of 1 mf/kg and 10 mg/kg for 13 weeks, 5 days a week, has enabled the absence of mortality to be established.
Pharmacolo~ical tests Pharmacological experiments with animals comes up chiefly against two practical difficulties: on the one hand, it is difficult to create locally, at the level of the nasal fossae, an experimental infection which does not get better spontaneously in a space of time too short for the test to be conclusive; on the other hand, nebulization or spraying, which is a form of administration well adapted ~0 to man, is scarcely so adapted to animals, which accept 1~8~31 instillation or exposure to an aerosol mist better.
To solve these difficulties, four series of tests have been used:
a) Immunolo~ical ~roPerties in vitro of the ~ anti~enic fractions and of a mixture thereof in accordance with Com~osition I and II.
It is demonstrated that the extracts of the nine strains (Staphvlococcus aureus 634, 636 and 659, StrePtococcus 147, Streptococcus P~o~enes 115 and 1178, DiPlococcus neumoniae 209 and 210 and Neisseria catarrhalis 987) possess an anti-genic structure by employing Kolmer's method; in fact, each fraction obtained in accordance with Example A and the mixture of the said fractions give a positive reaction with the immunoserums produced in animals (rabbits) by injection of suspensions of each of the nine strains in formaldehyde (the said suspension is obtained by adding formaldehyde to the nutrient culture medium of Example A containing the strain and by the centrifuging).
b) Immunisation by the parenteral method with the anti~enic fractions and a mixture thereof in accordance with Compositions I and II
Three times a week, for 4 weeks, there is administered to rabbits by the injection method 2 mg per day of each of the antigenic fractions entering into Com-positions I and II (the antigenic fraction extracted from Neisseria catarrhalis being excluded, since this would in~olve a risk of causing shock by the parenteral method).
The serum of the animals is then taken, which is tested with the 9 antigenic fractions and the mixture thereof by Kolmer's method and that of Ouchterlony. The results of 1~4~931 the two methodsenable it to be affirmed that the antl-genic fractionq and the mixture thereof produce a good immunisation of the animals.
c) Sho inR_antibodies~at_the level of the nasal mucous membrane in treated animals.
The experiments were made by instillation (rats) and aerosol (guinea pigs); the results being concordant, - only the tests relating to the rats have been summarised hereinafter.
1~ Record The experiments were conducted on 40 rats distributed as follows:
Control batch:
Male SPF rats (average weight 250 g) Nos. 1 to 10 1~ ~emale SPF rats (average weight 250 g) Nos. 11 to 20 Treated batch:
Male SPF rats (average weight 250 g) Nos. 21 to 30 Female SPF rats (average weight 250 g) Nos. 31 to 40 The animals were treated nasally at the rate of 11 drops per nostril, twice a day, for 8 weeks, with a solution of the mixture of the nine antigenic fractions entering into the Composition I of Example B. This solution contained 5 g of mixture of purified antigenic fractions for 100 ml of distilled water.
The control batch received only distilled water under the same conditions.
At the end of eight weeks of treatment, the animals were sacrificed and the nasal mucous membranes were removed.
The nasal mucous membrances were then washed with p~ysiological serum and milled in the presence of 0 5 ml of isotonic solution of sodium chloride. Once the milled products had been centrifuged, the supernatant material was used for carrying out the Kolmer reaction against the anti-staphylococcus, antistreptococcus, antipneumococcus and antineisseria immunoserums and proving the presence of antibodies.
Results The results, animal by animal, for each batch, are given in Tables I and II; these results have moreover been regrouped in Tables III and IV, respectively, to be expressed in % according to the indications of the Kolmer reaction.
d) Showin~ the Protective ProPerties in vivo of the anti-~eni~ ractions in relation to exPerimental infections with Streptococci and Sta~hylococci.
As it was difficult to create a rhino-pharyngeal infection useful for experiments in animals, subcutaneous abscesses were caused in guinea pigs by injection of a microbial dose close to the minimum in~ectious dose (MID) of Streptococcus pyogenes 155 (MID = 005 ml of the 24-hour culture medium of this strain) and of Staphylococcus aureus 636 (MID = 0-5 ml of the 24-hour culture medium of this strain). The mixture of the antigenic fractions (excluding the Neisseria catarrhalis fraction)was then administered intramuscularly at the rate of 8 mg/kg of the said mixture every day for 5 weeks. In comparison with the infected control animals not receiving the said mixture, it was observed that the treated animals were better protected.
. 1~48931 ' CONTR~I BATCH
_ .. _. ..... _ Rats Antistaphylococcus Streptococcus Antipneumococcus .~ntineisseria Nos. antiserum antiserum antiserum antiserun : ~ ~ ~
J _ _ 1 __ . - KOL~ER REAC~J.ON
- Legend: - negative reaction + slightly positive reaction + positive reaction ++ very po itive reaction ~ 16 1~48931 ~ , . .
. ~AB~E II
TREA~'~D BA~CH
. ~ ....... _ . , Rats Antistaphylococcus Streptococcus Antipneumococcus Antineisseria No~. antiserum antiserum antiserum antiserum~ -~ L
-.
~ . ABLE TII
CONTROL B.~rCH
.~ . , eXpre~sed ¦AntiStta~hylococous Streptococcus antiseru~ nantsseeria :. _ _ - ne~ative 65 ~0 75 % 100 % 100 9 + slightly .
~ positive 15 ~ 10 90 .
+ positive 20 ~, 5 ~ _ positive - _ ~ _ TAB~E IV
TR~ATED BATCH
.
e~precsed antiserum 3 iseru~ Antipneumococcus antiseru~ 1 ,. . . .
- ne~ative 10 ~ . 15 % 25 ~ 25 + ~lightly .
~ positive 15 ~0 20 jo 45 ~0 50 ~0 + positive 55 ~ 55 ~ 30 ~ 25 '~
positivF 20 ~ 10 ~ _ ~ ' ., , . I
- I
48931 . I
. ~ . . .
Clinical experiments were carried out using t~e co~position oi ~xa~ple B. The effects of this composition on oto-rhino-laryn~ological infections and also the immunizing : power created in relation to the germ9 isolated both in children and in adults were studied. Parallel with this, in~estigætion of the level of i.~muno Bobulins o~ the secretory Ig~ type at the le~el of the na~al mucous ~as , undertaken before and after treatment.
These clinical experiments, concerned with 50 ~ætients .di~tributed in age groups as indic~ted i~ Table V and suffering ~rom . a) rhinitis and rhino-pharyngitis, 'b) recurrent otitis and/or . . c) sinusitis, gave the ag~re~ate results contained in Table VI.
'TAB~E V
. . ..
, Age No. of Cases Dosage ._ , . . .
0 - 5 years 3 ' Onc,e in each nostril . . . twice a day __ 5 - 10 years 22 . Once in e~ch nostril . . three times a dæy ... .. . . . . .
10 - 20 years 10 Twice in eac~ nostril twice a day 20 years and . . .
.above 15 Twice in each nostril . . three times a day .
. .
. Note: (a) duration of treatment: 2 - 3 weeks . .
.
.
.... . ~._ 1~48~31 ?AB~ VI
. .. . . . ._ ' . Overall results.
.__ _ _ . _ ..
Results No, o~ Caseæ ,percenta~e . . _ _ ..... _ .
Very good 3 6 1 Gooa 34 '' 68 ~ = 82 .
Average . .4 8 J
. . .
Negat~ve ~ _ 18 In the 82~" of positive re ~ ts in ~able VI,. effectiveness was observed ~rom the 15th day of treatment. This effectiveness was found to be lasting, since the majority of the ,~atients showed no recurrence of symptoms during a period of 2 to months after the end of the treatr~ent, ~o case of intolerance was observed in any of the 50 patients.
1~4893~
FLOW CEIART
CULTURE
~I
LYSIS OF BACTERIA
I
DESTRUCTION OF BACTERIA
1, SEPARATION (1) ANTIGENIC SOLID BACTERIAL RESIDUES -->
FRACTION +
LIQUID
\~
ABSORPTION OF
ANTIGENIC FRACTION
SEPARATION (2) ABSORBED LIQUID
SOLID FRACTION
\~1 !
ELUTION
~ ~"
ELUATE ABSORBANT -----~
~I
SEPARATION (3) CONCENTRATION ELUANT -~
LYOPHILISATION
ANTIGEN
A fresh passage through a centrifuge is carried out in order to recover the antigenic fractions adsorbed on the carbon, which will then be eluted with the aid of an aqueous solution of ammonia.
The antigenic fractions are then contained in the ammonia water.
The solution undergoes treatment in an evaporator, the object of this operation being to eliminate the ammonia and concentrate the aqueous solution. The concentration of the said aqueous solution is effected under conventional conditions; the aim to be attained is an antigenic fraction content which can be lyophilised. It is thus possible to concentrate from 2 volumes to 1 volume or, better still, from 5 volumes or more to 1 volume.
~,~,' ~48931 The lyophilisation of this aqueous solution constitutes the final stage of the extraction.
The purified antigenic fractions are then in the form of powder.
II - PreParation of the anti~enic fraction extracted from Neisseria Catarrhalis In this instance there is no change of principle, but the culture medium is different (this is due to the difficulty of cultivating this germ); moreover, the culture is performed in a 5-litre flask and lasts for 48 hours.
Only the differences in comparison with the preparation of the antigenic ~ractions extracted from Staphylococcus aureus, Streptococcus and Diplococcus Pneumoniae are given here.
Culture medium Horse serum 250 ml T broth quantitr æufficient for5 litres Composition of the T broth Peptone 200 g Glucose 10 g NcCl 25 g Distilled water quantity sufficient for 5 litres For the preparation of this medium, the horse serum is introduced sterilely into the sterile T broth and the pH is adjusted to 7-2.
The medium is then sterilized at 100C for 45 minutes.
The lysis of the bacteria, the extraction of the antigenic fractions and then the lyophilisation are then effected by the method hereinbefore described for the -1~)4893~
Staph~lococcus, Streptocooous and Diplococcus.
The molecular weight of each of the 9 antigenic fractions obtained according to ~ and II is about 12,000.
III - Mixin~ of the various anti~enio ~ractions 1 part by weight of the purified and lyophilised antigenic fraction of Neisseria catarrhalis is mixed with 3 parts by weight of each of the purified and lyophilised antigenic fractions of ~ aureus 634, 636 and 659, Streptococcus 147, 155 and 1178 and Diplococcus Pneumoniae 209 and 210.
Example B
The preferred composition according to the invention was prepared by reproducing Example A and mixing the antigenic fractions of the nine straîns in Stage III with sodium mercuro-thiolate, sodium chloride and water so as to obtain the following formulation:
Composition I:
Purified antigenic fraction extracted from ~ 634 3 mg Purified antigenic fraction extracted from Staphylococcus aureus 636 3 mg Purified antigenic fraction extracted from 5taphylococcus aureus 659 3 mg Purified antigenic fraction extracted from Streptococcus 147 3 mg Purified antigenic fraction extracted from Streptococcus p,~og~nes 155 3 mg Purified antigenic fraction extracted from Streptococcus E~ 1178 3 mg Purified antigenic fraction extracted from Diplococcus pneumonia 209 3 mg Purifled antigenic fraction extracted from DiPloc_ccus ~a~ 210 3 mg Purified antigenic fraction extracted from Neisseria catarrhalis 1 mg Sodium mercurothiolate 0-25 mg Sodium chloride 90 mg Distilled water quantity sufficient for 10 ml ~ y proceeding as above, a composition II was prepared observing the proportion of composition I.
Composition II
Purified antigenic fraction extracted from Staph,ylococcus aureus 634 4-5 mg Purified antigenic fraction extracted from StaphYlococcus aureus 636 4-5 mg Purified antigenic fraction extracted from Staph~lococcus aureus 659 4 ~ 5 mg Purified antigenic fraction extracted from Streptococcus 147 4a5 mg Purified antigenic fraction extracted from Streptococcus P~o~e-n-es 155 4 - 5 mg Purified antigenic fraction extracted from Strept coccus pyo~enes 1178 4~5 mg Purified antigenic fraction extracted from Diplococcus pneumoniae 209 4~ 5 mg Purified antigenic fraction extracted from Diploc_ccus pn,eumon,iae 210 4 ~ 5 mg Purified antigenic fraction extracted from Neisseria catarrhalis 987 1 5 mg ~ ; ~
Sodium mercurothiolate o~ 375 mg Sodium chloride 135 mg Distilled water quantity sufficient for 15 ml 16~48931 Composition II packaged in 15 ml bottles for the purpose of being administered by spraying into the nasal fossae has been called provisionally by the names "Rhinapten"
and "Rhinapten Nebuliseur". The results of the pharmacological ~5 and clinical tests which have been undertaken are summarized hereinafter.
Toxicity Study of the acute toxicity in mice, per os, has enabled it to be shown that the LD~0 (minimum mortal dose) of each of the nine antigenic fractions entering into compositions I and II is higher than 4 g/kg. It has also been shown that the LD-0 of the mixture of the nine anti-genic fractions is distinctly higher than 108 g/kg and that the LD-0 o~ compositions I and II is e~ual to 40 ml/kg (which corresponds to a dose of the mixture of the nine antigenic fractions of 100 mg/kg).
Study of the actue toxicity in mice and rats, ~er os, of the mixture of the nine antigenic fractions entering into compositions I and II at doses of 1 mf/kg and 10 mg/kg for 13 weeks, 5 days a week, has enabled the absence of mortality to be established.
Pharmacolo~ical tests Pharmacological experiments with animals comes up chiefly against two practical difficulties: on the one hand, it is difficult to create locally, at the level of the nasal fossae, an experimental infection which does not get better spontaneously in a space of time too short for the test to be conclusive; on the other hand, nebulization or spraying, which is a form of administration well adapted ~0 to man, is scarcely so adapted to animals, which accept 1~8~31 instillation or exposure to an aerosol mist better.
To solve these difficulties, four series of tests have been used:
a) Immunolo~ical ~roPerties in vitro of the ~ anti~enic fractions and of a mixture thereof in accordance with Com~osition I and II.
It is demonstrated that the extracts of the nine strains (Staphvlococcus aureus 634, 636 and 659, StrePtococcus 147, Streptococcus P~o~enes 115 and 1178, DiPlococcus neumoniae 209 and 210 and Neisseria catarrhalis 987) possess an anti-genic structure by employing Kolmer's method; in fact, each fraction obtained in accordance with Example A and the mixture of the said fractions give a positive reaction with the immunoserums produced in animals (rabbits) by injection of suspensions of each of the nine strains in formaldehyde (the said suspension is obtained by adding formaldehyde to the nutrient culture medium of Example A containing the strain and by the centrifuging).
b) Immunisation by the parenteral method with the anti~enic fractions and a mixture thereof in accordance with Compositions I and II
Three times a week, for 4 weeks, there is administered to rabbits by the injection method 2 mg per day of each of the antigenic fractions entering into Com-positions I and II (the antigenic fraction extracted from Neisseria catarrhalis being excluded, since this would in~olve a risk of causing shock by the parenteral method).
The serum of the animals is then taken, which is tested with the 9 antigenic fractions and the mixture thereof by Kolmer's method and that of Ouchterlony. The results of 1~4~931 the two methodsenable it to be affirmed that the antl-genic fractionq and the mixture thereof produce a good immunisation of the animals.
c) Sho inR_antibodies~at_the level of the nasal mucous membrane in treated animals.
The experiments were made by instillation (rats) and aerosol (guinea pigs); the results being concordant, - only the tests relating to the rats have been summarised hereinafter.
1~ Record The experiments were conducted on 40 rats distributed as follows:
Control batch:
Male SPF rats (average weight 250 g) Nos. 1 to 10 1~ ~emale SPF rats (average weight 250 g) Nos. 11 to 20 Treated batch:
Male SPF rats (average weight 250 g) Nos. 21 to 30 Female SPF rats (average weight 250 g) Nos. 31 to 40 The animals were treated nasally at the rate of 11 drops per nostril, twice a day, for 8 weeks, with a solution of the mixture of the nine antigenic fractions entering into the Composition I of Example B. This solution contained 5 g of mixture of purified antigenic fractions for 100 ml of distilled water.
The control batch received only distilled water under the same conditions.
At the end of eight weeks of treatment, the animals were sacrificed and the nasal mucous membranes were removed.
The nasal mucous membrances were then washed with p~ysiological serum and milled in the presence of 0 5 ml of isotonic solution of sodium chloride. Once the milled products had been centrifuged, the supernatant material was used for carrying out the Kolmer reaction against the anti-staphylococcus, antistreptococcus, antipneumococcus and antineisseria immunoserums and proving the presence of antibodies.
Results The results, animal by animal, for each batch, are given in Tables I and II; these results have moreover been regrouped in Tables III and IV, respectively, to be expressed in % according to the indications of the Kolmer reaction.
d) Showin~ the Protective ProPerties in vivo of the anti-~eni~ ractions in relation to exPerimental infections with Streptococci and Sta~hylococci.
As it was difficult to create a rhino-pharyngeal infection useful for experiments in animals, subcutaneous abscesses were caused in guinea pigs by injection of a microbial dose close to the minimum in~ectious dose (MID) of Streptococcus pyogenes 155 (MID = 005 ml of the 24-hour culture medium of this strain) and of Staphylococcus aureus 636 (MID = 0-5 ml of the 24-hour culture medium of this strain). The mixture of the antigenic fractions (excluding the Neisseria catarrhalis fraction)was then administered intramuscularly at the rate of 8 mg/kg of the said mixture every day for 5 weeks. In comparison with the infected control animals not receiving the said mixture, it was observed that the treated animals were better protected.
. 1~48931 ' CONTR~I BATCH
_ .. _. ..... _ Rats Antistaphylococcus Streptococcus Antipneumococcus .~ntineisseria Nos. antiserum antiserum antiserum antiserun : ~ ~ ~
J _ _ 1 __ . - KOL~ER REAC~J.ON
- Legend: - negative reaction + slightly positive reaction + positive reaction ++ very po itive reaction ~ 16 1~48931 ~ , . .
. ~AB~E II
TREA~'~D BA~CH
. ~ ....... _ . , Rats Antistaphylococcus Streptococcus Antipneumococcus Antineisseria No~. antiserum antiserum antiserum antiserum~ -~ L
-.
~ . ABLE TII
CONTROL B.~rCH
.~ . , eXpre~sed ¦AntiStta~hylococous Streptococcus antiseru~ nantsseeria :. _ _ - ne~ative 65 ~0 75 % 100 % 100 9 + slightly .
~ positive 15 ~ 10 90 .
+ positive 20 ~, 5 ~ _ positive - _ ~ _ TAB~E IV
TR~ATED BATCH
.
e~precsed antiserum 3 iseru~ Antipneumococcus antiseru~ 1 ,. . . .
- ne~ative 10 ~ . 15 % 25 ~ 25 + ~lightly .
~ positive 15 ~0 20 jo 45 ~0 50 ~0 + positive 55 ~ 55 ~ 30 ~ 25 '~
positivF 20 ~ 10 ~ _ ~ ' ., , . I
- I
48931 . I
. ~ . . .
Clinical experiments were carried out using t~e co~position oi ~xa~ple B. The effects of this composition on oto-rhino-laryn~ological infections and also the immunizing : power created in relation to the germ9 isolated both in children and in adults were studied. Parallel with this, in~estigætion of the level of i.~muno Bobulins o~ the secretory Ig~ type at the le~el of the na~al mucous ~as , undertaken before and after treatment.
These clinical experiments, concerned with 50 ~ætients .di~tributed in age groups as indic~ted i~ Table V and suffering ~rom . a) rhinitis and rhino-pharyngitis, 'b) recurrent otitis and/or . . c) sinusitis, gave the ag~re~ate results contained in Table VI.
'TAB~E V
. . ..
, Age No. of Cases Dosage ._ , . . .
0 - 5 years 3 ' Onc,e in each nostril . . . twice a day __ 5 - 10 years 22 . Once in e~ch nostril . . three times a dæy ... .. . . . . .
10 - 20 years 10 Twice in eac~ nostril twice a day 20 years and . . .
.above 15 Twice in each nostril . . three times a day .
. .
. Note: (a) duration of treatment: 2 - 3 weeks . .
.
.
.... . ~._ 1~48~31 ?AB~ VI
. .. . . . ._ ' . Overall results.
.__ _ _ . _ ..
Results No, o~ Caseæ ,percenta~e . . _ _ ..... _ .
Very good 3 6 1 Gooa 34 '' 68 ~ = 82 .
Average . .4 8 J
. . .
Negat~ve ~ _ 18 In the 82~" of positive re ~ ts in ~able VI,. effectiveness was observed ~rom the 15th day of treatment. This effectiveness was found to be lasting, since the majority of the ,~atients showed no recurrence of symptoms during a period of 2 to months after the end of the treatr~ent, ~o case of intolerance was observed in any of the 50 patients.
1~4893~
FLOW CEIART
CULTURE
~I
LYSIS OF BACTERIA
I
DESTRUCTION OF BACTERIA
1, SEPARATION (1) ANTIGENIC SOLID BACTERIAL RESIDUES -->
FRACTION +
LIQUID
\~
ABSORPTION OF
ANTIGENIC FRACTION
SEPARATION (2) ABSORBED LIQUID
SOLID FRACTION
\~1 !
ELUTION
~ ~"
ELUATE ABSORBANT -----~
~I
SEPARATION (3) CONCENTRATION ELUANT -~
LYOPHILISATION
ANTIGEN
Claims (13)
1. A process for the preparation of a therapeutically-active product, which comprises separately cultivating in a liquid nutrient medium containing a source of carbon, a source of nitrogen and mineral salts the strains of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus 147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209, Diplococcus pneumoniae 210 and Neisseria catarrhalis 987 of the catalogue of the collec-tion of the Centre International de Distribution de Souches et d'Informations sur les Types Microbiens of Lausanne; for each of said strains, effecting enzymatic lysis of the strain in the culture medium at 60 to 65°C using papain and then at 37°C using trypsin, destroying each enzyme after use by heating at 100° to 120°C for 30 minutes, eliminating solid substances of bacterial origin which result from the lysis by centrifuging, adsorbing the antigenic fraction contained in the liquid medium after centri-fuging on a solid support, separating the solid support from the liquid phase by centrifuging, eluting the antigenic fraction from the support using an aqueous solution of ammonia, evapora-ting ammonia from the eluate, concentrating the eluate, and lyophilising the concentrate eluate to obtain the antigenic fraction in the form of powder; and mixing the separately-obtained lyophilised antigenic fractions in the proportions of 3 parts by weight of each of the lyophilised antigenic fractions of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus 147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209 and Diplococcus pneumoniae 210 and 1 part by weight of the lyophilised antigenic fraction of Neisseria catarrhalis 987.
2. The process of claim 1, wherein said nutrient medium for the cultivating of each of the strains with the exception of Neisseria catarrhalis 987 comprises: 1500 g of NaCl, 1500 g. of dipotassium phosphate, 600 g of monopotassium phosphate, 600 g of monoammonium phosphate, 1500 g of glucose, 60 g of magnesium sulphate, 600 g of glycerine, 600 g of yeast autolyzate, 6 g of manganese sulphate, 1.50 g of thiamine hydrochloride, 1.50 g of pyridoxine hydrochloride, 1.50 g of calcium pantothenate, 1.50 g of nicotinic acid, 0.75 g of riboflavin and water to a total of 300 liters.
3. The process of claim 1, wherein said nutrient medium for cultivating the strain of Neisseria catarrhalis 987 is grown in a nutrient medium comprising 250 ml of horse serum, 200 g of peptone, 10 g of glucose, 25 g of NaCl and water up to a volume of 5 litres.
4. The process of claim 1, wherein said enzymatic lysis using papain is carried out at pH 6.5 for 3 hours and using trypsin is carried out at pH 7 for 3 hours.
5. The process of claim 1, wherein said solid support is charcoal.
6. The process of claim 1, 2 or 3, wherein each of said antigenic fractions has a molecular weight of about 12,000.
7. The process of claim 1, 2 or 3, including the further step of mixing the mixture of antigenic fractions with 0.25 part by weight of sodium mercurothiolate, 90 parts by weight of NaCl and water to 10 parts by volume.
8. The process of claim 1, 2 or 3, including the further steps of mixing the mixture of antigenic fractions with 0.25 part by weight of sodium mercurothiolate, 90 parts by weight of NaCl and water to 10 parts by volume, and packaging the resulting aqueous composition in 15 ml nasal spray bottles
9. A therapeutically-active product prepared by the process of claim 1, or its obvious chemical equivalent thereof.
10. A therapeutically-active product prepared by the process of claim 8, or by an obvious chemical equivalent thereof.
11. A therapeutically-active product prepared by a process comprising: separately cultivating the strains of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus 147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209 and Diplococcus pneumoniae 210 of the catalogue of the Collection of the Centre International de Distribution de Souches et d'Informations sur les Types Microbiens of Lausanne, in a liquid nutrient medium comprising 1500 g of NaCl, 1500 g of dipotassium phosphate, 600 g of mono-potassium phosphate, 600 g of monoammonium phosphate, 1500 g of glucose, 60 g of magnesium sulphate, 600 g of glycerine, 600 g of yeast autolyzate, 6 g of manganese sulphate, 1.50 g of thiamine hydrochloride, 1.50 g of pyridoxine hydrochloride, 1.50 g of calcium panthothenate, 1.50 g of nicotinic acid, 0.75 g of riboflavin and water to a total of 300 litres, separately cultivating the strain of Neisseria catarrhalis 987 of the catalogue of the Collection of the Centre International de Distribution de Souches et d'Information sur les Types Microbiens of Lausanne, in a liquid nutrient medium comprising 250 ml of horse serum, 200 g of peptone, 10 g of glucose, 25 g of NaCl and water to a volume of 5 litres; for each of the strains, effecting enzymatic lysis of the strain at 60° to 65°C and a pH of 6.5 for 3 hours using papain and then at 37°C and a pH of 7 for 3 hours using trypsin, inactivating the enzymes after use by heating at 100° to 120°C for 30 minutes, eliminating solid substances of bacterial origin by centrifuging the medium resulting from the enzymatic lysis, absorbing the antigenic fraction contained in the liquid medium after centrifuging on charcoal, separating the charcoal from the liquid phase by centrifuging, eluting the antigenic fraction from the charcoal using an aqueous solution of ammonia, evaporating ammonia from the eluate, concentrating the eluate, and lyophilising the con-centrated eluate to obtain the antigenic fraction in the form of powder; and mixing the separately-obtained lyophilised antigenic fractions in the proportions of 3 parts by weight of each of the antigenic fractions of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus 147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209 and Diplococcus pneumoniae 210 and 1 part by weight of the antigenic fraction of Neisseria catarrhalis 987, or by an obvious chemical equiva-lent thereof.
12. The product of claim 11, wherein the lyophilised anti-genic fractions are also mixed with 0.25 parts by weight of sodium mercurothiolate, 90 parts by weight of NaCl and 10 parts by volume of distilled water.
13. The product of claim 12, packaged in 15 ml bottles in a manner to be sprayed or nebulized into nasal fossae and con-stituted by 4.5 mg each of the antigenic fraction of Staphylococcus aureus 634, Staphylococcus aureus 636, Staphylococcus aureus 659, Streptococcus 147, Streptococcus pyogenes 155, Streptococcus pyogenes 1178, Diplococcus pneumoniae 209 and Diplococcus pneumoniae 210, and 1.5 mg of the antigenic fraction of Neisseria catarrhalis 987, 0.375 mg of sodium mercurothiolate, 135 mg of NaCl and water in sufficient quantity to the volume of 15 ml.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB38984/74A GB1518277A (en) | 1974-09-06 | 1974-09-06 | Antigenic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1048931A true CA1048931A (en) | 1979-02-20 |
Family
ID=10406910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA75234882A Expired CA1048931A (en) | 1974-09-06 | 1975-09-05 | Bacterial antigen composition for treatment of oto-rhinolaringological infections |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPS5161624A (en) |
AR (1) | AR205836A1 (en) |
BE (1) | BE832959A (en) |
CA (1) | CA1048931A (en) |
CH (1) | CH606437A5 (en) |
DE (1) | DE2539622A1 (en) |
DK (1) | DK394075A (en) |
ES (1) | ES440773A1 (en) |
FR (1) | FR2283697A1 (en) |
GB (1) | GB1518277A (en) |
IL (1) | IL48066A (en) |
NL (1) | NL7510575A (en) |
SE (1) | SE7509913L (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH633188A5 (en) * | 1978-05-26 | 1982-11-30 | Om Laboratoires Sa | MEDICINE FOR INFECTIOUS DISEASES OF THE RESPIRATORY TRACT. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1553099A (en) * | 1967-11-30 | 1969-01-10 |
-
1974
- 1974-09-06 GB GB38984/74A patent/GB1518277A/en not_active Expired
-
1975
- 1975-01-01 AR AR260277A patent/AR205836A1/en active
- 1975-09-01 FR FR7526754A patent/FR2283697A1/en active Granted
- 1975-09-01 BE BE159649A patent/BE832959A/en unknown
- 1975-09-02 DK DK394075A patent/DK394075A/en unknown
- 1975-09-05 SE SE7509913A patent/SE7509913L/en unknown
- 1975-09-05 CH CH1153975A patent/CH606437A5/xx not_active IP Right Cessation
- 1975-09-05 DE DE19752539622 patent/DE2539622A1/en not_active Withdrawn
- 1975-09-05 IL IL48066A patent/IL48066A/en unknown
- 1975-09-05 ES ES440773A patent/ES440773A1/en not_active Expired
- 1975-09-05 CA CA75234882A patent/CA1048931A/en not_active Expired
- 1975-09-06 JP JP50108452A patent/JPS5161624A/ja active Pending
- 1975-09-08 NL NL7510575A patent/NL7510575A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FR2283697B1 (en) | 1979-03-23 |
NL7510575A (en) | 1976-03-09 |
ES440773A1 (en) | 1977-03-16 |
SE7509913L (en) | 1976-03-08 |
JPS5161624A (en) | 1976-05-28 |
FR2283697A1 (en) | 1976-04-02 |
AR205836A1 (en) | 1976-06-07 |
BE832959A (en) | 1976-03-01 |
IL48066A0 (en) | 1975-11-25 |
DE2539622A1 (en) | 1976-03-18 |
CH606437A5 (en) | 1978-11-30 |
IL48066A (en) | 1978-01-31 |
GB1518277A (en) | 1978-07-19 |
DK394075A (en) | 1976-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Belton et al. | Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production | |
RU2194531C2 (en) | Polyvalent associated diphtheria, tetanus toxoids and pertussis poliovirus vaccines | |
CA1231643A (en) | Composition of intravenous immune globulin | |
EP0648127B1 (en) | Type i surface antigens associated with staphylococcus epidermidis | |
JPH04501429A (en) | Method for inactivating viruses in pharmaceutical compositions contaminated with viruses | |
WO2017006349A1 (en) | Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides | |
JPH05506649A (en) | Method for purifying B. pertussis outer membrane protein | |
EP1748063B1 (en) | Protein A production and purification without using animal derived components | |
NZ566871A (en) | Protein A Production and Purification without Using Animal Derived Components involving staphylococcus aureus | |
US20220267419A1 (en) | Human Immunoglobulin Against Methicillin-Resistant Staphylococcus Aureus, Preparation Method Therefor, And Use Thereof | |
KR100401423B1 (en) | A Manufacturing Method of Combined Vaccine | |
US4349540A (en) | Process for preparing vaccines based on antigenic ribosomal fractions | |
EP0691348A1 (en) | Immunogenic compositions prepared from adenylate cyclase of B. Parapertussis | |
DD202623A5 (en) | PROCESS FOR PREPARING SPORES POLYOSIDES | |
CA1048931A (en) | Bacterial antigen composition for treatment of oto-rhinolaringological infections | |
KR0169982B1 (en) | Drug for the treatment of dermatitis | |
US5225194A (en) | Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases | |
PL126416B1 (en) | Method of obtaining immunobiotherapeutic preparation counteractive against respiratory system diseases | |
CA1117866A (en) | Haemophilus influenzae vaccine | |
UA121358C2 (en) | INACTIVATED STAFFILOCOCCAL LIQUID VACCINE, METHOD OF PREPARATION AND METHOD OF TREATMENT AND PREVENTION BY IT | |
Burans et al. | Kinetics of Haemophilus influenzae type B infection in normal and ribosome-immunized mice using intraperitoneal and intracerebral routes of inoculation. | |
KR100250714B1 (en) | Therapeutic agent for treating infections of pseudomonas aeruginosa | |
KR970001704B1 (en) | Pseudomonas infection preventing vaccines using attenuated pseudomonas cfcpa 20215 | |
KR970001708B1 (en) | Pseudomonas infection preventing vaccines using attenuated pseudomonas cfcpa 60534 | |
KR970001709B1 (en) | Pseudomonas infection preventing vaccines using attenuated pseudomonas cfcpa 70018 |